Methods of treatment using IL-18 receptor antigen binding proteins
AssigneeAmgen Inc.
InventorsDirk E. Smith, John E. Sims, Jeffrey T. McGrew, Marek Z. Kubin, Duncan Cochrane, Louise Conroy
Life of this patent
Estimating the term…
Abstract
Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor.
Claims14
A method for treating a condition associated with IL-18 receptor in a patient, comprising administering to a patient in need thereof a pharmaceutical composition comprising an antigen binding protein that binds the IL-18 receptor, wherein said antigen binding protein comprises:
- an antibody heavy chain comprising (a) a CDRH1 of SEQ ID NO:104;
- (b) a CDRH2 of SEQ ID NO:105;
- and (c) a CDRH3 of SEQ ID NO:106;
- and
- an antibody light chain comprising (a) a CDRL1 of SEQ ID NO:173;
- (b) a CDRL2 of SEQ ID NO:174;
- and (c) a CDRL3 of SEQ ID NO:175.
A method of inhibiting the binding of IL-18 to IL-18 receptor comprising contacting an IL-18 receptor with an antigen binding protein comprising:
- an antibody heavy chain comprising (a) a CDRH1 of SEQ ID NO:104;
- (b) a CDRH2 of SEQ ID NO:105;
- and (c) a CDRH3 of SEQ ID NO:106;
- and
- an antibody light chain comprising (a) a CDRL1 of SEQ ID NO:173;
- (b) a CDRL2 of SEQ ID NO:174;
- and (c) a CDRL3 of SEQ ID NO:175,
- wherein said antigen binding protein binds said IL-18 receptor and prevents binding of said IL-18 receptor to IL-18.
Dependencies are inferred from the claim text.